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There is growing recognition of cerebrovascular con-
tributions to neurodegenerative diseases. In thewalls
of cerebral arteries, amyloid-beta (Ab) accumulation
is evident in a majority of aged people and patients
with cerebral amyloid angiopathy. Here, we leverage
human pluripotent stem cells to generate vascular
smooth muscle cells (SMCs) from neural crest pro-
genitors, recapitulating brain-vasculature-specific
attributes of Abmetabolism.Weconfirm that the lipo-
protein receptor, LRP1, functions in our neural-crest-
derived SMCs to mediate Ab uptake and intracellular
lysosomal degradation. Hypoxia significantly com-
promises the contribution of SMCs to Ab clearance
by suppressing LRP1 expression. This enabled us
to develop an assay of Ab uptake by using the neural
crest-derived SMCs with hypoxia as a stress para-
digm. We then tested several vascular protective
compounds in a high-throughput format, demon-
strating the value of stem-cell-based phenotypic
screening for novel therapeutics and drug repurpos-
ing, aimed at alleviating amyloid burden.
INTRODUCTION
Neurodegenerative disorders such as Alzheimer’s disease affect
millions of people globally and pose major public health chal-
lenges. Amyloid plaques and neurofibrillary tangles are the pri-
mary hallmarks of Alzheimer’s disease. There is now an
increasing recognition that the vascular system could play a
causative role to some of these pathologies in the brain.
Amyloid-beta (Ab), a peptide processed from the amyloid pre-
cursor protein (APP), drains from the brain with interstitial fluid
and becomes deposited in the blood vessels walls as cerebral
amyloid angiopathy (CAA) (Soffer, 2006). CAA is implicated in
80% of Alzheimer’s disease patients and 10%–40% of elderly
without Alzheimer’s disease (Jellinger, 2010; Viswanathan and
Greenberg, 2011). Down’s syndrome patients also have promi-nent CAA because of duplication of the APP locus, resulting in
elevated Ab burden (Rovelet-Lecrux et al., 2006; Sleegers
et al., 2006). In normal physiology, cellular uptake and subse-
quent proteasomal degradation of Ab are the principal means
of metabolizing Ab with little accumulation in the central nervous
system (Nedergaard, 2013). Extracellular elimination routes also
play a part in clearance through the blood-brain barrier and
transportation to liver. Cerebrovascular smooth muscle cells
(SMCs) and astrocytes are known to be able to remove Ab
locally via the low-density lipoprotein receptor-related protein
1 (LRP1)-mediated endocytic pathway (Kanekiyo et al., 2012).
On the other hand, LRP1 reductions have been reported in
Alzheimer’s disease patients and LRP1 also appears to decrease
significantly with age (Deane and Zlokovic, 2007). Brains of pa-
tients with severe CAA are often exposed to chronic hypoxia
due to cerebral blood dysregulation and microhaemorrhages
(Farkas and Luiten, 2001). Previous studies have demonstrated
that hypoxia is associatedwith lowered LRP1 expression in cere-
bral SMCs (Bell et al., 2009). LRP1 downregulation in vascular
cellsmay lead todysfunctional local Abprocessing, exacerbating
the growth of para-arterial Ab deposits in CAA. Secondary
neuronal degeneration may further cause cognitive impairment
and dementia. Therefore, the need to identify therapeutic inter-
ventions targeting neurovascular complexities is critical.
Animal models have been indispensable for the studies of CAA
(Winkler et al., 2001; Herzig et al., 2004). Considering the caveat
of interspecies disparity, judicious interpretation is requiredwhen
extrapolating results from animal research to human biology.
Drug discovery has traditionally relied on immortalized target-ex-
pressing cell line and human primary cells for screening. The lim-
itation of the former is the lack of biological interactome whereas
the latter oftenhas toomuchbatch-to-batch variation, and isdiffi-
cult to obtain in sufficient quantities. It would be valuable to
develop a human in vitro system that simulates the pathophysio-
logical characteristics of cerebral vasculatures. The advent of
human pluripotent stem cells (hPSCs) such as embryonic stem
cells (hESCs) and induced pluripotent stem cells (iPSCs) could
provide a source of SMCs for modeling pathological processes
in CAA to facilitate interrogation of molecular mechanisms.
There is compelling evidence that SMCs in different regions
of the vasculature originate from diverse embryonic lineagesCell Reports 9, 391–401, October 9, 2014 ª2014 The Authors 391
(Majesky, 2007). In CAA, Ab accumulation occurs predominantly
in the wall of intracerebral and leptomeningeal arteries (Soffer,
2006), both of which are derivatives of the neural crest lineage
(Li et al., 2013). Here, we report the generation of SMCs from
hPSCs via a neural crest population. We found that SMCs of
various embryonic origins had different extent of compromised
Ab uptake upon hypoxic treatment and that LRP1 regulated Ab
processing in our neural crest-derived SMCs. Finally, we devel-
oped a phenotypic assay of Ab uptake and validated it by pilot
screening of pharmaceutical compounds in a high-throughput
format.
RESULTS
Derivation of Neural Crest-Specific Vascular SMCs
Themajority of studies to date have focused on the generation of
generic SMCs, which may confound potential lineage-specific
differences (Cheung and Sinha, 2011). We and others have at-
tempted the derivation of origin-specific SMCs from hPSCs
(Cheung et al., 2012; Wang et al., 2012). For the purpose of
modeling cerebral SMCs, we tested different chemical cocktails
based on factors known to promote neural crest differentiation in
hPSCs (Chambers et al., 2009; Menendez et al., 2013) (Fig-
ure S1A). Because activation of canonical Wnt signaling had
shown to induce neural crest formation in hPSCs, we tested an
inhibitor of glycogen synthase kinase 3, CHIR99021. Bone
morphogenetic protein (BMP) antagonist noggin was included
to counteract mesodermal induction due to endogenous BMP
signaling in hPSCs. A combination of basic fibroblast growth fac-
tor (bFGF, 12 ng/ml), activin/nodal inhibitor SB431542 (10 mM),
noggin (200 ng/ml) resulted in peaked expressions of neural
crest markers between days 10 and 16 of hPSC (hESCH9) differ-
entiation (Figure 1A). We monitored the development of neural
crest surface markers (Figure S1B) and found that both FSb
(bFGF + SB431542) and FSbN (bFGF + SB431542 + noggin)
conditions yielded substantial amount (>65%) of double NGFR
and B3GAT1 expressing cells on day 10. Isolated NGFR+/
B3GAT1+ cells from FSbN treatment confirmed greater expres-
sion levels of neural crest genes than those from FSb treatment
(Figure 1B). Hence, these NGFR+/B3GAT1+ cells were purified,
following FSbN treatment, to perform subsequent differentiation
into vascular SMCs.
We adopted our previous SMC differentiation protocol
(Cheung et al., 2012) to differentiate this intermediate neural
crest population using platelet-derived growth factor BB
(PDGF-BB, 10 ng/ml) and transforming growth factor-beta 1
(TGF-b1, 2 ng/ml) for another 12 days. The resultant neural
crest-derived SMCs (NCSMCs) were then characterized in com-
parison to neuroectoderm-derived SMCs (NESMCs) (Cheung
et al., 2012) and positive control, human brain vascular SMCs
(BVSMCs). The source of BVSMCs used in this work has been
employed in several studies as a model of human cerebrovascu-
lar SMCs (Kanekiyo et al., 2012; Lefterov et al., 2010; Zuloaga
and Gonzales, 2011; Yao et al., 2014; Shi et al., 2014). A panel
of SMC-related genes was upregulated in all SMC subtypes
derived from both hESCs (H9) and iPSCs (BJ-iPSCs) as
compared to hPSCs (Figure 1C). NCSMCs demonstrated com-
parable levels of TAGLN (Figure 1D), an actin crosslinking protein392 Cell Reports 9, 391–401, October 9, 2014 ª2014 The Authorsfound in smooth muscle, and contractile protein ACTA2 (Fig-
ure 1E), as NESMCs and BVSMCs. Furthermore, NCSMCs ex-
hibited contractile ability with reduction of cell surface area in
response to a vasoconstrictor, angiotensin II (Figure 1F). Waves
of calcium influx were detected by fluo-4 imaging during
contraction (Figure S1C; Movies S1, S2, S3, and S4). These re-
sults verified that the NCSMCs were functional. To determine
whether our NGFR+/B3GAT1+ neural crest population was
indeed multipotent, we carried out neuronal differentiation (Hu
and Zhang, 2009). The neural crest cells were found to give
rise to network structures stained positive for neuronal markers
TUBB3 and MAP2 (Figure S1D).
NCSMCs Demonstrate Cerebrovascular-Relevant
Amyloid-b Uptake Ability
To model after cerebrovascular SMCs with high fidelity, we
investigated whether NCSMCs shared the closest molecular sig-
natures and functional characteristics with BVSMCs than the
SMC subtypes originating from other embryonic origins (e.g.,
neuroectoderm, lateral plate mesoderm, and paraxial meso-
derm) (Cheung et al., 2012). Unless otherwise stated, most ex-
periments were performed using SMC subtypes were derived
hESC (H9). Gene expression analysis showed that NCSMCs
derived from either hESCs (H9) or iPSCs (BJ-iPSCs) clustered
more closely with BVSMCs than NESMCs in the gene ontology
(GO) category of brain development (Figure 2A; genes listed in
Table S1). Functional annotation of the commonly enriched
genes in all SMC subtypes indicated GO categories such as
blood vessel development and extracellular matrix organization
as expected (Figure S2A). Common genes specific only to
BVSMCs and NESMCs demonstrated functions pertaining to
blood vessel development, but therewere also irrelevant GOcat-
egories like skeletal system and bone development. On the other
hand, NCSMCs seemed to share more specialized functions
with BVSMCs in integrin-mediated pathway (adhesion), epithe-
lial cell differentiation (necessary for neural crest specialization),
response to calcium (contractile ability), and smooth muscle
development. Hence, we postulated that BVSMCs could
resemble more closely to NCSMCs than NESMCs.
Because oxygen deprivation could be an initiating event in the
pathogenesis of CAA, we cultured the various SMC subtypes at
1%oxygen for at least 2 weeks to induce chronic hypoxia. All the
SMC subtypes responded with an upregulation of hypoxia-
inducible factor-1a (Figure S2B). Internalization of Ab by lipopro-
tein receptors on SMCs was reported to be compromised by
hypoxic conditions (Bell et al., 2009). Low-density lipoprotein re-
ceptor (LDLR) mediated Ab uptake and cell death of cerebral
perivascular cells (Wilhelmus et al., 2007). Cerebrovascular cells
and neurons also express different Ab-degrading enzymes
including neprilysin (MME), tissue plasminogen activator
(PLAT), and matrix metalloproteinases (Zlokovic, 2011). MME
is downregulated in both hypoxia (Wang et al., 2011) and
Alzheimer’s disease patients manifesting CAA (Miners et al.,
2006). By gene expression quantification, we found that LRP1,
LDLR, MME, and PLAT were significantly downregulated in a
majority of the SMC subtypes, with the greatest reduction
observed in NCSMCs and NESMCs compared to their counter-
parts that were cultured at 21% oxygen (Figure 2B). Protein
Figure 1. Characterizations of Neural Crest-Derived Vascular SMC
(A) Quantitative RT-PCR of neural crest markers during FSb (bFGF + SB431542) and FSbN (bFGF + SB431542 + noggin) treatments on hPSCs. FSbN was more
effective than FSb at inducing neural crest gene expressions between day 10 and day 16.
(B) FACS-sorted NGFR+/B3GAT1+ cells from FSb- and FSbN-treated populations were profiled for neural crest genes. Data represent means ± SEM (n = 3).
Statistical differences compared to FSbN samples were calculated with Student’s t test (*p < 0.05, **p < 0.01, **p < 0.001).
(C) Microarray gene expression heatmap of SMC markers in hPSCs versus positive control, human brain vascular SMCs (BVSMCs), neural crest SMCs
(NCSMCs), and neuroectoderm SMCs (NESMCs) obtained from hESC (H9) and iPSCs (BJ-iPSCs) after differentiation. Orange (upregulation) and blue (down-
regulation) depict differential gene expression from the mean across all samples.
(D) NCSMCs, NESMCs, and positive control, BVSMCs, were immunostained positively for SMC contractile protein, TAGLN. Human umbilical vein endothelial
cells (HUVECs) were used as a negative control.
(E) Flow cytometric analysis of SMC protein, ACTA2, in NC and NE before SMC differentiation, as well as in NCSMCs and NESMCs after differentiation. Numbers
on the plots indicate percentage of ACTA2+ cells. A substantial proportion of cells in each SMC subtype was positive for ACTA2 (88%–95%).
(F) All SMC subtypes displayed contractile ability in response to angiotensin II. HeLa cells were used as a negative control. There was 18%–21% reduction of cell
surface area in contracting SMCs. Data represent means ± SEM (n = 30). Scale bar, 50 mm.
See also Figure S1.
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Figure 2. Chronic Hypoxia Compromises Ab Uptake Differentially in SMC Subtypes
(A) Clustering of genes from the gene ontology category of brain development revealed that the molecular signatures of NCSMCs associated more closely with
BVSMCs than NESMCs.
(B) A comparison of the effect of 21% versus 1% oxygen on the gene expressions of lipoprotein receptors and Ab-degrading enzymes in different SMC subtypes.
(C) Flow cytometric analysis of the percentage of LRP1+ cells in SMC subtypes. One percent oxygen significantly decreased LRP1 expression in all SMC
subtypes. The black bars on the histogram plots demarcate the gating for quantifying the percentages of LRP1-expressing cells.
(D) Uptake of fluorescently labeled Ab40 and Ab42 peptides by SMC subtypes after 3 hr was measured by flow cytometry. Cell-associated Abwas calculated as
mean brightness of the cells with Ab uptake as a ratio to their respective no-uptake control cells at 21% and 1% oxygen.
Data represent means ± SEM (n = 3). Statistical differences compared to 21% oxygen samples were calculated with ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
Statistical differences compared to day 0 were calculated with ANOVA (yp < 0.001). See also Figure S2.analysis showed decreased percentage of LRP1-expressing
cells in the SMC subtypes at 1% oxygen (Figure 2C). LRP1 is
abundantly expressed in the cerebral vasculatures, in particular,
the SMCs (Lillis et al., 2008). We found that more than 50% of394 Cell Reports 9, 391–401, October 9, 2014 ª2014 The AuthorsNCSMCs expressed LRP1, constituting to the highest percent-
age of LRP1+ cells among the SMC subtypes (Figure 2C, right
panel). Taking into consideration the difference in abundance
of LRP1 protein per cell, the median fluorescent intensity of
LRP1-FITC in each of the SMC populations also decreased
significantly at 1% oxygen (Figure S2C).
Ab40 is the chief form of vascular amyloid component in CAA,
whereas Ab42 may be responsible for early-stage damage
(Alonzo et al., 1998). Ab deposits in parenchyma and blood ves-
sels seem to be originated from neuronal-derived Ab as animal
studies indicated that local production of Ab by cerebrovascular
cells was not essential to drive CAA pathology (Winkler et al.,
2001; Calhoun et al., 1999). To examine hPSC-derived SMCs’
ability to uptake exogenous Ab, we first treated BVSMCs with
fluorescently labeled Ab40 and Ab42 peptides (2 mg/ml). Ab inter-
nalization via LRP1 requires the presence of serum lipoprotein
(Urmoneit et al., 1997). At different time points after the onset
of Ab uptake in serum-containing media, we measured the
mean fluorescence brightness by flow cytometry to determine
the amount of cell-associated Ab in BVSMCs (Figure S2D). The
rate of Ab uptake slowed down after 3 hr, so we carried out
3 hr Ab uptake for subsequent experiments. To investigate the
effect of hypoxia on uptake of exogenous Ab, we treated all
the SMC subtypes with fluorescently labeled Ab40 and Ab42
peptides. In compliance with an abundance of LRP1 expression
found in cerebral vasculatures (Lillis et al., 2008), and the highest
LRP1 expression showed in Figure 2C, NCSMCs demonstrated
greatest uptake of Ab40 and Ab42 at 21% oxygen (Figure S2E).
After the cells were cultured at 1% oxygen, hypoxia attenuated
the amount of cell-associated Ab, especially for NCSMCs
(Ab40, p = 0.000324; Ab42, p = 0.000723) and NESMCs (Ab40,
p = 0.000229; Ab42, p = 0.000556) (Figure 2D). On the other
hand, the uptake of Ab40 was not compromised in LMSMCs or
PMSMCs under 1% oxygen, suggesting that such mesodermal
derivatives may not mediate Ab uptake primarily through
LRP1-dependent pathway. Differences in Abmetabolism among
the SMC subtypes seemed to have already been influenced early
by the differences in spatiotemporal development of neural crest
and mesoderm. Nonneural crest SMC subtypes may not fully
recapitulate the biology of cerebrovascular-specific attributes.
We further tested if in vitro Ab metabolism could be assayed
under more physiological conditions (Verghese et al., 2013). Up-
take of Ab in NCSMCs increased in a concentration-dependent
manner (Figure S2F). We chose 300 ng/ml as a near-physiolog-
ical concentration, which yielded a relatively well-detectable
readout to proceedwith Ab uptake under 1%oxygen. Consistent
with previous experiments, hypoxia attenuated the amount of
cell-associated Ab40 and Ab42 in BVSMCs (Ab40, p =
0.00105; Ab42, p = 0.00304) and NCSMCs (Ab40, p = 0.00015;
Ab42, p = 0.00290) (Figure S2G). However, no significant change
was observed in NESMCs, suggesting that hypoxia-induced
alteration to Ab uptake at physiological range may not be repro-
ducible in NESMCs. Hence, NCSMC was the most appropriate
SMC subtype for reproducing the pathophysiological features
of cerebral vasculatures in Ab metabolism.
NCSMCs Recapitulate LRP1-Mediated Amyloid-b
Clearance
SMC-specific knockout of Lrp1 in an amyloid mouse model
accelerated brain Ab accumulation and CAA (Kanekiyo et al.,
2012). LRP1 suppression in brain primary SMCs significantly
diminished their ability to uptake and degrade exogenous Ab.To study whether Ab processing in NCSMCs was regulated by
LRP1, we performed gene silencing of LRP1 using small inter-
fering RNA (siRNA). At least 3-fold reduction of LRP gene (p =
0.0120) (Figure S3A) and protein levels (p = 0.00144) (Figure 3A)
was achieved in comparison to the scrambled siRNA controls.
LRP1 knockdown resulted in compromised uptake of both
Ab40 (p = 0.0000558) and Ab42 (p = 0.000101) in NCSMCs (Fig-
ure 3B). Intracellular lysosomal degradation of Ab following up-
take also depends on the presence of LRP1 (Kanekiyo et al.,
2012). To study Ab clearance after cellular uptake, we employed
the use of ELISAs. LRP1 siRNA- and scrambled siRNA-treated
NCSMCs were first incubated with 5 mg/ml of human recombi-
nant Ab for 3 hr in serum-containing medium. Total cell lysates
were then collected at days 0, 2, and 5 after uptake for analysis.
NCSMCs had low endogenous Ab before uptake (Figure 3C). Af-
ter uptake, scrambled control NCSMCs possessed significantly
higher amounts of Ab40 (p = 0.00103) and Ab42 (p = 0.0224) than
the LRP1 siRNA-treated NCSMCs. Intracellular Ab decreased
over time with LRP1 siRNA-treated NCSMCs showing slower
rate of Ab42 clearance than scrambled siRNA-treated NCSMCs
(Figure 3D). By day 5, degradation of both Ab40 (p = 0.0495) and
Ab42 (p = 0.0432) was significantly compromised by LRP1
silencing in NCSMCs. In the LRP1 siRNA-treated NCSMCs, we
observed different rate of degradation with Ab40 being cleared
more efficiently than Ab42. This could suggest that the presence
of Ab-degrading proteases could contribute to the differential
degradation kinetics of distinct forms of Ab (Leissring and
Turner, 2013). Clearance of Ab peptides was also affected in
the positive control BVSMCs as evident in the significantly higher
amounts of remnant Ab40 (p = 0.00336) and Ab42 (p = 0.000291)
in the LRP1 siRNA-treated BVSMCs after 2 days of degradation
(Figure S3B). Other SMC subtypes appeared to have inconsis-
tent extent of Ab clearance in response to LRP1 silencing, indi-
cating that SMCs of other embryonic origins might not fully reca-
pitulate lipoprotein receptor-mediated Ab metabolism.
To investigate whether LRP1 played a role in lysosomal degra-
dation of Ab in our NCSMCs, we used a lysotracker dye to image
for any colocalization of fluorescently labeled Abwith lysosomes.
Live cells were monitored at days 0, 3, and 7 after 3 hr of Ab up-
take. The results supported the above finding that LRP1 siRNA-
treated NCSMCs had compromised Ab clearance as traces of
incorporated Ab in lysosomes were still found at days 3 and 7
but not for the control NCSMCs (Figure 3E). Like previously
described in human cerebrovascular SMCs, we confirmed that
LRP1 functioned in our NCSMCs to facilitate intracellular Ab
degradation. The involvement of other lipoprotein receptors
and Ab-degrading proteases in Ab clearance can be further
explored using our NCSMC system.
Amyloid pathology in the brain is often accompanied by SMC
atrophy (Blaise et al., 2012). We also studied the effect of recom-
binant Ab on cell death of NCSMCs. Hypoxic condition exacer-
bated apoptosis of NCSMCs as evident by annexin V staining
(Figure S3C). Higher concentrations of recombinant Ab only re-
sulted in minor increase in the proportion of apoptotic cells at
1% oxygen. We recognized the limitation of modeling Ab-
induced SMC death in vitro as substantial SMC loss in the lepto-
meningeal artery of patients was a consequence of chronic
exposure to Ab deposits. Hence, for the aim of improvingCell Reports 9, 391–401, October 9, 2014 ª2014 The Authors 395
Figure 3. LRP1 Mediates Ab Clearance in NCSMCs
(A) Flow cytometric analysis confirmed more than 3-fold LRP1 protein knockdown in LRP1 siRNA-treated NCSMCs compared to scrambled control.
(B) LRP1 silencing in NCSMCs resulted in significantly reduced uptake of fluorescently labeled Ab peptides in 3 hr as measured by flow cytometry.
(C) ELISA validated the decreased internalization of exogenous recombinant Ab peptides in LRP1-suppressed NCSMCs after 3 hr uptake.
(D) Intracellular Abwas monitored over time by ELISA on NCSMC cell lysates after 3 hr uptake of recombinant Ab peptides. Ab degradation was evident from the
drop in Ab levels by day 2, but NCSMCs with LRP1 knockdown were not as effective as scrambled controls in the elimination of internalized Ab peptides.
(E) NCSMCswere imaged at days 0, 3, and 7 after a 3 hr uptake of fluorescently labeled Ab40 (green) and Ab42 (red) peptides.White arrows indicate incorporation
of labeled Ab in lysosomes (blue). Scale bar, 100 mm.
Data represent means ± SEM (n = 3). Statistical differences compared to scrambled controls were calculatedwith Student’s t test for two groups or by ANOVA for
three or more groups (*p < 0.05, **p < 0.01, **p < 0.001). See also Figure S3.vascular health, NCSMCs could be used to develop a pheno-
typic assay of Ab uptake.
High-Throughput Assay of Amyloid-b Uptake for
Screening of Reference Compounds
To attain the eventual goal of cell-based phenotypic screening,
we selected a panel of reference pharmaceutical compounds
for testing. Patients on statin prescriptions for lowering circu-
lating cholesterol to prevent cardiovascular diseases were re-
ported to have lower incidence of neurodegenerative disorders
and improved cognitive performance, probably due to pleio-
tropic vascular protective effects of drugs (Whitfield, 2007). Sta-
tins prevent late-onset Alzheimer’s disease by stimulating LRP1
expression on brain vascular cells (Deane et al., 2004). Rifam-396 Cell Reports 9, 391–401, October 9, 2014 ª2014 The Authorspicin, an antibiotic, enhances Ab clearance by inducing LRP1
expression at the blood-brain barrier (Qosa et al., 2012). Another
antibiotic, minocycline (Choi et al., 2007), and angiotensin recep-
tor blockers (Li et al., 2010) are able to attenuate the progression
of dementia, but there is not yet direct evidence that they target
the Ab clearance machinery. We tested the reference com-
pounds on NCSMCs cultured at 1% oxygen and found that
statins and rifampicin upregulated the gene and protein expres-
sions of lipoprotein receptors (Figures 4A and 4B). These drugs
were further evaluated for their potential benefits on Ab uptake
in NCSMCs.
To develop high-throughput screening capability on our
NCSMCs, we had to choose a sensitive and disease-relevant
readout, in this case, uptake of labeled Ab peptides. We scaled
Figure 4. Testing of Vascular Protective Compounds in a High-Throughput Ab Uptake Assay
(A) Reference drugs were treated on NCSMCs at 1% oxygen for 48 hr to investigate whether the compounds could rescue the compromised gene expressions of
lipoprotein receptors by chronic hypoxia.
(B) Flow cytometric analysis of LRP1 and LDLR protein expression after 48 hr of compound treatment on NCSMCs at 1% oxygen.
(C) Z factor is a statistical measurement of the feasibility of a cell-based phenotypic assay for high-throughput screening. Averagemeasurements on ‘‘fold change
of mean brightness relative to no-uptake control’’ and SDs were obtained from positive (grown at 21% oxygen) and negative (grown at 1% oxygen) controls. The
means and SDs of both positive (p) and negative (n) controls are indicated as (mp, sp) and (mn, sn), respectively. A value of more than 0.5 indicates a robust Ab
uptake assay, whereas a value of between 0 and 0.5 is a marginal assay.
(D) Reference drugs were treated on NCSMCs for 48 hr prior to uptake of fluorescently labeled Ab peptides for an hour in a 96-well plate format. Cell-associated
Ab was evaluated by high-throughput flow cytometry.
Data represent means ± SEM (n = 3). Statistical differences compared to vehicle controls were calculated with Student’s t test (*p < 0.05, **p < 0.01, **p < 0.001).
See also Figure S3.down the NCSMC and BVSMC cultures to 96-well format. A
plating density of 30,000 cells/well yielded good postthawing
survival and reproducibility for assessment of Ab uptake.
SMCs, which were routinely grown at 21% oxygen, represented
the positive control, whereas SMCs conditioned to chronic hyp-
oxia at 1% oxygen were used as the negative control and exper-
imental samples. Cells were incubated with labeled Ab40 and
Ab42 (2 mg/ml) for an hour and subsequently evaluated by
high-throughput flow cytometry. Ab uptake in NCSMCs derived
from both hESC (H9) and iPSC (KYOUDXR0109B) resulted in
Z-factors of more than 0.5, indicative of a statistically robust
assay (Figure 4C). On the other hand, BVSMC produced a Z-fac-
tor between 0 and 0.5, which was considered only a marginal
assay. To prove the feasibility of drug screening, NCSMCs
derived from hESC (H9) were treated with reference compounds
and vehicle control for 48 hr, followed by uptake of Ab for another
hour. Among these reference compounds, only statins andrifampicin were reported to exert direct effects on upregulating
LRP1 and LDLR expression (Qosa et al., 2012; Pocathikorn
et al., 2010; Deane et al., 2004). Our findings revealed that ator-
vastatin (p = 0.0492) and rifampicin (p = 0.0174) significantly
increased Ab40 and Ab42 uptake, respectively, in NCSMCs
over the vehicle controls (Figure 4D). This could be due to
increased expression of the lipoprotein receptors although the
effects of such compounds on Ab uptake may occur through
other mechanisms as well. Minocycline and losartan may not
have any apparent effect and could be further investigated by
a dose-response experiment. Drug combinations appeared to
be countereffective because there were no significant beneficial
effects over the control. Likewise, NCSMCs derived from human
iPSC (KYOUDXR0109B) had identified rifampicin, which could
improve Ab uptake (Figure S3D), supporting the robustness of
NCSMC model for phenotypic screening. Taken together, we
have established a cell-based platform that is amenable forCell Reports 9, 391–401, October 9, 2014 ª2014 The Authors 397
high-throughput screening of novel compounds and for unravel-
ing beneficial effects of vascular protective compounds.
DISCUSSION
Vascular SMCs exist in a wide range of anatomic locations. Gene
expression profiling of SMCs from various tissues revealed het-
erogeneity in molecular signatures (Chi et al., 2007). The use of
appropriate SMC subtypes will be imperative for modeling the
functional and organ specializations (Majesky and Mummery,
2012). Capitalizing on the fact that cerebral SMCs could
contribute to Ab elimination by intracellular degradation, we
have derived NCSMCs of a neural crest origin in order to repro-
duce characteristics of neurovascular Ab metabolism. Indeed,
NCSMCs demonstrated more profound deficits in Ab uptake
than the other lineage-specific SMCs upon chronic hypoxic
treatment. Such intrinsic differences among SMC subtypes
could be attributed to their diverse embryonic origins. Success
of a cell-based assay will therefore rely on suitable lineage-
derived cell type, which is able to yield disease-relevant pheno-
typic readouts. We also recognize that other Ab clearance path-
ways could be better modeled in the presence of additional cell
types such as endothelial cells and astrocytes. There have been
progresses in obtaining brain-specific endothelial cells (Lipp-
mann et al., 2012) and astrocytes (Krencik and Zhang, 2011)
from hPSCs. This will open up avenues to create organotypic
system of the neurovascular unit toward the understanding of
CAA pathogenesis and neurological disorders.
CAA can be amultifactorial outcome due to environmental and
genetic predispositions. Besides hypoxia, Ab-induced NADPH
oxidase activation plays a part in vascular oxidative stress, lead-
ing to cerebrovascular dysfunction (Park et al., 2005). Arterial
stiffening in the aging brain diminishes the pulsatile forces for
drainage of interstitial fluid and solutes, causing Ab deposits in
the perivascular regions as CAA (Weller et al., 2009). Elevated
levels of inflammatory cytokines are also evident in the brain
microvasculature of Alzheimer’s disease individuals (Gorelick
et al., 2011). Our NCSMC resource can be adapted to interrogate
the effects of such risk factors. Genetic susceptibility to CAA has
been commonly studied in transgenic mice with mutant forms of
APP, which influence abnormal Abmetabolism and aggregation
(Herzig et al., 2004; Winkler et al., 2001). Patients with hereditary
cerebral amyloidosis were found to develop severe CAA, along
with hemorrhagic strokes and vascular dementia due to SMC
degeneration (Fossati et al., 2010). On the other hand, the differ-
ences in apolipoprotein E (APOE) genotypes seem to have
notable effect on the course of sporadic CAA as SMCs can inter-
nalize Ab via the lipoprotein pathway involving APOE (Ruzali
et al., 2013). Carrier of APOE4 showed increased incidence of
Ab accumulation, rendering the vessel walls more prone to vas-
culopathic rupture (Strittmatter et al., 1993; Schmechel et al.,
1993; Mazur-Kolecka et al., 2003). Patient iPSCs will provide a
valuable channel to capture these complex genotypes that pre-
dispose them to CAA. Patient NCSMCs generated from such
diseased iPSCs will serve as a useful model to study CAA-asso-
ciated pathological changes.
HPSC-based phenotypic screening is gainingmomentum as a
potential preclinical strategy for drug discovery (Zhang et al.,398 Cell Reports 9, 391–401, October 9, 2014 ª2014 The Authors2014; Lee et al., 2012; Ho¨ing et al., 2012; Yang et al., 2013). As
compared to the conventional hypothesis-driven target-based
screening, the phenotypic approach seeks to identify candidate
compounds with desired effects, without knowing the molecular
mechanism of action of drugs. Albeit more difficult to subse-
quently design chemical modifications for better results, pheno-
typic assay will be highly complementary as a secondary
screening to validate primary hits. In this work, our pilot testing
of pharmaceutical compounds is proof of concept that vascular
protective agents could mediate Ab uptake by SMCs in a high-
throughput manner. Many of these marketed compounds have
activity against vascular targets and have proven safety in
patients (Guan et al., 2011). Our NCSMC platform can also
be used in screening a smaller panel of FDA-approved drugs
for ameliorating vascular complications in neurological indica-
tions. Drug repurposing by cell-based phenotypic assay can
identify previously unknown therapeutic effects in order to inform
further mechanistic analysis, thereby shortening the lead time to
clinic.
EXPERIMENTAL PROCEDURES
Detailed experimental and analysis methods can be found in the Supplemental
Experimental Procedures.
HPSC Maintenance
H9 HESC line (WiCell) was cultured in a chemically defined medium (CDM) as
previously described (Brons et al., 2007). Human iPSCs were obtained by re-
programming human foreskin fibroblasts (BJs) into transgene-free iPSCs by
the Sendai viral vector method. These BJ-iPSCs were grown on irradiated
mouse feeders and cultured in DMEM/F12medium, containing 20%Knockout
serum replacement (Gibco) and 4 ng/ml FGF-2 (R&D Systems). We have also
used commercially available human iPSCs (KYOUDXR0109B, ATCC), which
were derived from dermal fibroblasts obtained from a healthy adult donor.
These fibroblasts were reprogrammed by the expression of OCT4, SOX2,
KLF4, and MYC using retroviral transduction and subsequently cultured in
the conditions as stated above.
NCSMC Differentiation
For neural crest differentiation, hPSCs were grown in CDM + bFGF (12 ng/ml,
R&D systems) + SB431542 (10 mM, Sigma) + noggin (200 ng/ml, R&DSystems)
for 10–13 days, with change of medium every 2–3 days. After which, NGFR+/
B3GAT1+ cells were isolated by fluorescence-activated cell sorting (FACS)
and replated for SMC induction. Sorted cells were cultured in SMC differenti-
ation medium CDM + PDGF-BB (10 ng/ml, PeproTech) + TGF-b1 (2 ng/ml,
PeproTech) for another 12 days. Derived NCSMCs could be propagated
further in culture using SMC medium (SC-1101, Sciencell). All experiments
were done on NCSMCs between passages 1 and 9. On the other hand, the
other SMC subtypes (NESMC, LMSMC, and PMSMC) were generated by a
previously established protocol (Cheung et al., 2012).
Source of BVSMCs
The human brain vascular smooth muscle cells (BVSMCs) were acquired
from a commercial source, ScienCell Research Laboratories (cat no. #1100)
and cultured using SMC medium (SC-1101, Sciencell). All experiments were
done on BVSMCs between passages 1 and 9. The SMC medium contains
essential and nonessential amino acids, vitamins, organic and inorganic
compounds, hormones, growth factors, traceminerals and fetal bovine serum,
smooth muscle growth supplements, and penicillin/streptomycin solution.
Ab Peptide Uptake Measurement by Flow Cytometry
SMC subtypes were incubated with 2 mg/ml of fluorescently labeled amyloid
peptide (Ab42-Hilyte Fluor 555 or Ab40-Hilyte Fluor 488, Anaspec) at 37C
for a 3 hr uptake unless otherwise stated. After Ab uptake, cells were dissoci-
ated into single-cell suspension for flow cytometric analysis by Becton Dickin-
son FACSCalibur. Mean fluorescence brightness was calculated from each Ab
uptake sample in triplicates and normalized to the mean fluorescence bright-
ness of no-uptake control samples. Relative comparisons of cell-associated
Ab in SMC subtypes were then plotted.
High-Throughput Ab Uptake Assay Development
NCSMCs and BVSMCswere routinely cultured at 21%oxygen and 1%oxygen
to simulate normoxic and chronic hypoxic conditions, respectively. Twenty-
one percent O2 SMCs were seeded at 30,000 cells/well onto 96-well plate
as positive controls. One percent O2 SMCs were seeded at the same density
as negative controls and experimental samples for drug treatment on the same
plate. The 96-well plate was incubated at 37C overnight at 21% O2. After cell
attachment, 2 mg/ml of fluorescently labeled amyloid peptide (Ab42-Hilyte
Fluor 555 or Ab40-Hilyte Fluor 488, Anaspec) was added to SMCs for a 1 hr
uptake at 37C. After Ab uptake, cells were dissociated into single-cell suspen-
sion for high-throughput flow cytometry by LSRFortessa plate analyzer.
Respective Z factors for NCSMC and BVSMC Ab uptake assays were calcu-
lated based on their mean fluorescence brightness (normalized to no-uptake
controls) and SDs of positive (21% O2) and negative (1% O2) controls. For
the experimental samples with drug treatment, NCSMCs were incubated
with reference compounds (i.e., atorvastatin, simvastatin, rifampicin, minocy-
cline, losartan, and vehicle control) for 48 hr prior to Ab uptake. Mean fluores-
cence brightness signals (normalized to no-uptake control) indicated the
degree of amyloid uptake.
Statistical Analysis
Results are presented as mean ± SEM of three independent experiments
unless otherwise stated. Statistical p values were calculated by Student’s t
test for two groups or by ANOVA for three or more groups. Significant differ-
ences are indicated as *p < 0.05, **p < 0.01, and **p < 0.001 unless otherwise
stated.
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